Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental vaccine aims to stop lung cancer from coming back

NCT ID NCT05642195

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times

Summary

This trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remaining cancer cells and prevent the cancer from returning. Up to 30 adults with no signs of active disease after surgery will receive the vaccine and N-803 over several months, with close monitoring for safety and immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant, with or without N-803 (IL-15 superagonist)
What this could lead to
If successful, this could offer a new immunotherapy option to reduce the risk of lung cancer returning after surgery for patients with PD-L1 negative tumors.
What could go wrong
This is an early phase 1/2 trial with only 30 participants, currently suspended. The vaccine is experimental, and it is unknown if it will effectively prevent recurrence or cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma Neoplasm, Residual non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG CARCINOMAS NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.